Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could sharpen prostate cancer detection

NCT ID NCT07689656

Recruiting now Diagnosis Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests a new radioactive imaging agent called [68Ga]Ga-ELI421 for PET scans in people with prostate cancer. The goal is to see if it is safe and can accurately highlight cancer cells in the body. Researchers will also measure how the agent spreads and how much radiation it delivers. The trial involves 50 adults with confirmed prostate cancer who need a PSMA PET scan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[68Ga]Ga-ELI421 injection (a radioactive imaging agent)
What this could lead to
If successful, this could provide a more precise way to detect and monitor prostate cancer using PET scans, potentially improving diagnosis and treatment planning.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 50 participants, so the imaging agent may not prove safe or effective in larger, more diverse groups. There is also a small risk of radiation exposure from the radioactive tracer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.